Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54 - Wikidata - awgldk - TriplyDB

Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54

Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54

http://www.wikidata.org/entity/Q35482151

about

New and emerging targeted therapies for cystic fibrosis Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis Robust Stimulation of W1282X-CFTR Channel Activity by a Combination of Allosteric Modulators The unfolded protein response affects readthrough of premature termination codons Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor New trends in aminoglycosides use.Increased selectivity toward cytoplasmic versus mitochondrial ribosome confers improved efficiency of synthetic aminoglycosides in fixing damaged genes: a strategy for treatment of genetic diseases caused by nonsense mutations Nonsense-mediated decay in genetic disease: friend or foe?Suppression of premature termination codons as a therapeutic approach.A comparative evaluation of NB30, NB54 and PTC124 in translational read-through efficacy for treatment of an USH1C nonsense mutation A review of patents (2011-2015) towards combating resistance to and toxicity of aminoglycosides Designer aminoglycosides that selectively inhibit cytoplasmic rather than mitochondrial ribosomes show decreased ototoxicity: a strategy for the treatment of genetic diseases.Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator function.Impact of heterozygote CFTR mutations in COPD patients with chronic bronchitis.Therapeutics based on stop codon readthrough.Nonsense Suppression as an Approach to Treat Lysosomal Storage Diseases.Immunomodulatory effects of antimicrobial agents. Part I: antibacterial and antiviral agents.Managing the underlying cause of cystic fibrosis: a future role for potentiators and correctors.Strategies in early clinical development for the treatment of basic defects of cystic fibrosis.Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations.Targeting Nonsense Mutations in Diseases with Translational Read-Through-Inducing Drugs (TRIDs).When Proteins Start to Make Sense: Fine-tuning Aminoglycosides for PTC Suppression Therapy.Toward inclusive therapy with CFTR modulators: Progress and challenges.Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation.Identification of the amino acids inserted during suppression of CFTR nonsense mutations and determination of their functional consequences.Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons.

P2860

Q26749278-661B753E-AE4D-4017-9527-AF34EC567BD8 Q28073063-AAFC9CFD-176C-4C22-AF8D-E09685EB98AE Q28073996-892A8448-55DA-4684-8B35-5A2007E6D2CA Q28550950-3F5E9642-BDEB-4E8C-AB14-647713D6B26B Q33623379-14A994E8-C5CA-4978-B7BA-1BCE3069821D Q33799590-C64F6C4F-C78D-41FF-A045-142E66BBB227 Q33951177-D602AF86-B74A-46F8-B18C-A54366617BC0 Q34475657-B0E4BEF5-3881-443B-A895-499C5486FFB2 Q34658988-3506AA53-9775-4E6D-9F8D-97D03E8E74F1 Q36203719-5B058F82-3375-4586-B263-A8C6D0C8BEE0 Q36389318-ED76601C-9E1B-47B9-8EF7-0559B37FA8D6 Q36726249-3B42A77F-B88E-484B-8059-FA67AE32D0DA Q37511774-12B52E0F-2BEE-4443-A2DD-8E1790D3D5D8 Q37572359-6E7BA9BE-1903-4C7B-9E2A-6B344D72B02A Q37586134-E76DAE05-3864-4077-B6DE-73E45E4F2770 Q37638359-AA2DBA88-4141-4A0E-98FD-BDB7C8561280 Q37726532-974B7F1C-2A2F-4158-85CD-6ABE41A95B31 Q37991389-215E5E99-459A-44C8-A10A-3743B8DE8A57 Q38113749-2E70CD9D-003F-4CD6-BB72-E2B9B8B3EC45 Q38733938-4BA0B410-F3B6-4DAB-A08A-CDA2D3BD13BE Q38735278-C2D65B90-AE83-4106-BD36-921F82CA29DC Q38737126-BE745864-FF4B-4D73-B292-89A4B8A0EAEA Q42142778-8BC82EE4-D3C6-401C-BCF4-1AA8B79A2AD1 Q47842086-79A47B4A-082A-4BFA-BB81-7E2B8FF9179E Q50485119-C6E9D699-2A0A-4053-950B-ED44736DA867 Q50605358-926E7B26-C721-49E9-9D9F-69B5345E386D Q55497000-FB4A2975-1CD9-49CE-A6EC-668F3586B231

P2860

Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54

http://www.wikidata.org/entity/Q35482151

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Suppression of CFTR premature ...... synthetic aminoglycoside NB54

@ast

Suppression of CFTR premature ...... synthetic aminoglycoside NB54

@en

type

label

Suppression of CFTR premature ...... synthetic aminoglycoside NB54

@ast

Suppression of CFTR premature ...... synthetic aminoglycoside NB54

@en

prefLabel

Suppression of CFTR premature ...... synthetic aminoglycoside NB54

@ast

Suppression of CFTR premature ...... synthetic aminoglycoside NB54

@en

P1433

Q35482151-6B1227E5-60FF-4E65-A19F-82D8F67007CF

P1476

Q35482151-A330F857-2F31-4538-B8BD-57B93C1C37D9

P2093

Q35482151-3A4C056C-20BA-4B2A-80B1-11E79B3D6934

Q35482151-73DCEA2E-EFC0-4744-9E7E-83D5DBE85F6E

Q35482151-7A77C931-1820-439F-BABB-77EF718BA463

Q35482151-811233F5-9D93-4A83-B808-2EC265868E58

Q35482151-9CE4CB41-2198-49AB-9993-679F3D505348

Q35482151-B1840AD3-D0B0-4180-B4DB-F88F5403B341

Q35482151-B3090EC0-7BC4-4FBE-89D6-299ED51799A1

Q35482151-BAC4C9A7-8D03-4CB8-AE34-5340499B5589

Q35482151-BC78285D-9C6A-474B-A7CD-88E37E8E699B

Q35482151-CE7C9FAC-2B43-46C4-B671-2E496F724141

P2860

Q35482151-03CDD2AD-C8A5-4EBF-9603-809ACF4C5345

Q35482151-05332CA5-48E9-47A0-B007-8E7AB4C2E9C2

Q35482151-0D072146-3415-470E-B4D8-F4CBCC906D3B

Q35482151-14D05A2A-4AE2-4D06-8328-2FFF6F649515

Q35482151-18FB145B-5AA2-430D-9125-EA068347EA12

Q35482151-1936D492-8282-4919-BE7C-7F7C5B3BCFD7

Q35482151-21BF1CA2-BBEC-4B0D-8B99-0E59451B2E47

Q35482151-242ED33B-0EC4-4CF7-8E57-4A2457E12391

Q35482151-30328265-B5F5-4D95-8ACE-368195C5AF29

Q35482151-3FF1969D-0F65-4A6D-990C-87DAC07D2BEA

P2888

Q35482151-E83069E9-73FF-44C6-BD17-09740AC0D323

P304

Q35482151-9E56B4AB-D43F-423B-B2E1-CBE4C3D643EA

P31

Q35482151-9A81531B-ED44-47B8-B3AB-D7F9FACBC144

P356

Q35482151-13D4AD71-0116-4751-82FE-E4BDB64E4E5C

P433

Q35482151-64EA9A14-ED87-4A28-81C9-109749CA9195

P478

Q35482151-3B7F2B54-83A1-4B9A-A70E-85BE081D1EBA

P577

Q35482151-004A2D3E-69DA-4C7C-A8D5-9E5691611401

P5875

Q35482151-CCB573E6-E97C-4622-8593-06575FFA4EBC

P698

Q35482151-B933CFB6-E252-42B0-9D4F-FD4F336042BA

P932

Q35482151-0C076C4C-F67F-4632-880A-A1AE72F5CA5F

P356

S00109-011-0787-6

P1433

Journal of Molecular Medicine

P1476

Suppression of CFTR premature ...... synthetic aminoglycoside NB54

@en

P2093

David M Bedwell

http://www.w3.org/2001/XMLSchema#string

Erik Schwiebert

http://www.w3.org/2001/XMLSchema#string

Igor Nudelman

http://www.w3.org/2001/XMLSchema#string

Jessica Buckley-Lanier

http://www.w3.org/2001/XMLSchema#string

Kyle Backer

http://www.w3.org/2001/XMLSchema#string

Li Ping Tang

http://www.w3.org/2001/XMLSchema#string

Marina Mazur

http://www.w3.org/2001/XMLSchema#string

Peter Sloane

http://www.w3.org/2001/XMLSchema#string

Steven M Rowe

http://www.w3.org/2001/XMLSchema#string

Timor Baasov

http://www.w3.org/2001/XMLSchema#string

P2860

Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770

Cystic fibrosis

Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation.

In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study

Aminoglycosides: nephrotoxicity

Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations

Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice

DeltaF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers.

Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations.

Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system

P2888

s00109-011-0787-6

P304

1149-1161

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00109-011-0787-6

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

89

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51512402

http://www.w3.org/2001/XMLSchema#string

P698

21779978

http://www.w3.org/2001/XMLSchema#string

P932

3204584

http://www.w3.org/2001/XMLSchema#string